Hudson Thomas J 4
4 · AbbVie Inc. · Filed Feb 22, 2022
Insider Transaction Report
Form 4
AbbVie Inc.ABBV
Hudson Thomas J
SVP, R&D and CSO
Transactions
- Award
Common Stock, $0.01 par value
2022-02-17+2,530→ 43,544 total - Award
Common Stock, $0.01 par value
2022-02-17+11,642→ 41,014 total - Award
Common Stock, $0.01 par value
2022-02-17+9,483→ 53,027 total - Award
Common Stock, $0.01 par value
2022-02-17+6,609→ 59,636 total - Award
Option (Right to Buy)
2022-02-17+25,394→ 25,394 totalExercise: $144.54From: 2023-02-17Exp: 2032-02-16→ Common Stock (25,394 underlying)
Footnotes (5)
- [F1]Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022.
- [F2]Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022.
- [F3]Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022.
- [F4]Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022.
- [F5]Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 8,465 on February 17, 2023, 8,465 on February 17, 2024, and 8,465 on February 17, 2025.